Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post FY2026 Earnings of $1.44 Per Share, Zacks Research Forecasts

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Zacks Research decreased their FY2026 earnings estimates for shares of Esperion Therapeutics in a research note issued on Monday, May 6th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of $1.44 for the year, down from their prior forecast of $1.81. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.68) per share.

A number of other research analysts have also recently issued reports on ESPR. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Esperion Therapeutics in a research note on Tuesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $9.33.

Esperion Therapeutics Stock Down 13.9 %

Shares of ESPR traded down $0.33 during trading hours on Wednesday, reaching $2.04. 13,723,144 shares of the company traded hands, compared to its average volume of 7,041,883. The company's fifty day moving average price is $2.31 and its two-hundred day moving average price is $2.07. The company has a market capitalization of $386.38 million, a price-to-earnings ratio of -0.96 and a beta of 0.89. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business earned ($0.76) EPS.

Institutional Trading of Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in ESPR. Armistice Capital LLC bought a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $9,568,000. GSA Capital Partners LLP boosted its position in shares of Esperion Therapeutics by 159.1% in the third quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company's stock worth $1,094,000 after purchasing an additional 685,733 shares during the period. Monaco Asset Management SAM boosted its position in shares of Esperion Therapeutics by 68.5% in the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company's stock worth $1,148,000 after purchasing an additional 476,477 shares during the period. Wasatch Advisors LP boosted its position in shares of Esperion Therapeutics by 2.7% in the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company's stock worth $24,467,000 after purchasing an additional 238,544 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Esperion Therapeutics by 120.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 225,767 shares during the period. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.